Evidence map›Paper›PMID 25303561›Full record

ReviewBritish journal of pharmacology2015

Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?

Asif Ahmed, Wenda Ramma

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03648970 (Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03648970 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients

TypeinterventionalSponsorUniversitas AirlanggaRan2018 to 2020Enrolled280ConditionsPre-EclampsiaArmsPravastatin
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Frontiers in pharmacology · 2026
    Article
  4. Secondary prevention of preeclampsia.Frontiers in cell and developmental biology · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Placenta in the Critically Ill Mother.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Altered Tryptophan Catabolism in Placentas From Women With Pre-eclampsia.International journal of tryptophan research : IJTR · 2019
    Article
  20. Role of Aspirin in High Pulsatility Index of Uterine Artery: A Consort Study.Journal of obstetrics and gynaecology of India · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Asif AhmedVascular Therapeutics Unit, Aston Medical School, Aston University, Birmingham, UK.
Wenda Ramma
Aston University · GBHarvard University · US

Funding

British Heart Foundation RG/09/001/25940Medical Research Council G0600270Medical Research Council G0601295Medical Research Council G0700288Medical Research Council G0701824
6 · The paper itself

Abstract

Pre-eclampsia is a vascular disorder of pregnancy where anti-angiogenic factors, systemic inflammation and oxidative stress predominate, but none can claim to cause pre-eclampsia. This review provides an alternative to the 'two-stage model' of pre-eclampsia in which abnormal spiral arteries modification leads to placental hypoxia, oxidative stress and aberrant maternal systemic inflammation. Very high maternal soluble fms-like tyrosine kinase-1 (sFlt-1 also known as sVEGFR) and very low placenta growth factor (PlGF) are unique to pre-eclampsia; however, abnormal spiral arteries and excessive inflammation are also prevalent in other placental disorders. Metaphorically speaking, pregnancy can be viewed as a car with an accelerator and brakes, where inflammation, oxidative stress and an imbalance in the angiogenic milieu act as the 'accelerator'. The 'braking system' includes the protective pathways of haem oxygenase 1 (also referred as Hmox1 or HO-1) and cystathionine-γ-lyase (also known as CSE or Cth), which generate carbon monoxide (CO) and hydrogen sulphide (H2S) respectively. The failure in these pathways (brakes) results in the pregnancy going out of control and the system crashing. Put simply, pre-eclampsia is an accelerator-brake defect disorder. CO and H2S hold great promise because of their unique ability to suppress the anti-angiogenic factors sFlt-1 and soluble endoglin as well as to promote PlGF and endothelial NOS activity. The key to finding a cure lies in the identification of cheap, safe and effective drugs that induce the braking system to keep the pregnancy vehicle on track past the finishing line.

Indexed as

AnimalsCarbon MonoxideDrug DesignFemaleHumansHydrogen SulfideInflammationOxidative StressPlacentaPlacenta Growth FactorPre-EclampsiaPregnancyPregnancy ProteinsVascular Endothelial Growth Factor Receptor-1Carbon MonoxideHydrogen SulfidePGF protein, humanPlacenta Growth FactorPregnancy ProteinsVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID25303561
PMCPMC4354257
OpenAlexW1714905593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.